- Home
- TTNP vs ZVSA Comparison
TTNP vs ZVSA Comparison
Compare TTNP & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- ZVSA
- Stock Information
- Founded
- TTNP 1991
- ZVSA 2014
- Country
- TTNP United States
- ZVSA United States
- Employees
- TTNP N/A
- ZVSA N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- ZVSA Health Care
- Exchange
- TTNP Nasdaq
- ZVSA Nasdaq
- Market Cap
- TTNP 3.0M
- ZVSA 3.5M
- IPO Year
- TTNP 1996
- ZVSA N/A
- Fundamental
- Price
- TTNP $3.67
- ZVSA $1.22
- Analyst Decision
- TTNP
- ZVSA Strong Buy
- Analyst Count
- TTNP 0
- ZVSA 1
- Target Price
- TTNP N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- TTNP 25.0K
- ZVSA 69.7K
- Earning Date
- TTNP 03-31-2025
- ZVSA 03-24-2025
- Dividend Yield
- TTNP N/A
- ZVSA N/A
- EPS Growth
- TTNP N/A
- ZVSA N/A
- EPS
- TTNP N/A
- ZVSA N/A
- Revenue
- TTNP N/A
- ZVSA N/A
- Revenue This Year
- TTNP N/A
- ZVSA N/A
- Revenue Next Year
- TTNP N/A
- ZVSA N/A
- P/E Ratio
- TTNP N/A
- ZVSA N/A
- Revenue Growth
- TTNP N/A
- ZVSA N/A
- 52 Week Low
- TTNP $3.03
- ZVSA $0.98
- 52 Week High
- TTNP $14.80
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- TTNP 50.98
- ZVSA 44.26
- Support Level
- TTNP $3.35
- ZVSA $1.12
- Resistance Level
- TTNP $4.24
- ZVSA $1.29
- Average True Range (ATR)
- TTNP 0.29
- ZVSA 0.09
- MACD
- TTNP 0.02
- ZVSA -0.01
- Stochastic Oscillator
- TTNP 46.73
- ZVSA 37.04
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.